KLP Kapitalforvaltning AS Acquires Shares of 10,800 Repligen Co. (NASDAQ:RGEN)

KLP Kapitalforvaltning AS bought a new position in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,800 shares of the biotechnology company’s stock, valued at approximately $1,555,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Signaturefd LLC increased its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at approximately $37,000. Quarry LP raised its position in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the last quarter. UMB Bank n.a. raised its position in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Down 2.7 %

NASDAQ:RGEN opened at $133.41 on Friday. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $154.21 and a two-hundred day moving average price of $148.14. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $184.98.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Finally, Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of “Hold” and a consensus price target of $178.64.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.